Y-box-binding protein 1 (YB-1), which is a member of the DNA-binding protein family containing a cold-shock domain, has pleiotropic functions in response to various environmental stimuli. As we previously showed that YB-1 is a global marker of multidrug resistance in ovarian cancer and other tumor types. To identify YB-1-regulated genes in ovarian cancers, we investigated the expression profile of YB-1 small-interfering RNA (siRNA)-transfected ovarian cancer cells using a high-density oligonucleotide array. YB-1 knockdown by siRNA upregulated 344 genes, including MDR1, thymidylate synthetase, S100 calcium binding protein and cyclin B, and downregulated 534 genes, including CXCR4, N-myc downstream regulated gene 1, E-cadherin and phospholipase C. Exogenous serum addition stimulated YB-1 translocation from the cytoplasm to the nucleus, and treatment with Akt inhibitors as well as Akt siRNA and integrin-linked kinase (ILK) siRNA specifically blocked YB-1 nuclear localization. Inhibition of Akt activation downregulated CXCR4 and upregulated MDR1 (ABCB1) gene expression. Administration of Akt inhibitor resulted in decrease in nuclear YB-1-positive cancer cells in a xenograft animal model. Akt activation thus regulates the nuclear translocation of YB-1, affecting the expression of drug-resistance genes and other genes associated with the malignant characteristics in ovarian cancer cells. Therefore, the Akt pathway could be a novel target of disrupting the nuclear translocation of YB-1 that has important implications for further development of therapeutic strategy against ovarian cancers.
Introduction
The Y-box-binding protein 1 (YB-1), which is a DNA/ RNA-binding protein also known as dbpB, regulates transcription, translation, DNA damage repair and other biological processes in both the nucleus and cytoplasm (Matsumoto and Wolffe, 1998; Kohno et al., 2003) . In the cytoplasm, YB-1 regulates mRNA stability and translational regulation (Evdokimova et al., 2001; Ashizuka et al., 2002; Fukuda et al., 2004) , while in the nucleus, it plays a pivotal role in transcriptional regulation through specific recognition of the Y-box promoter element (Ladomery and Sommerville, 1995; Kohno et al., 2003) . Interaction of YB-1 with its cognate Y-box-binding site (inverted CCAAT box) is promoted by cytotoxic stimuli, including actinomycin D, cisplatin, etoposide, ultraviolet (UV) and heat shock, leading to the activation of a representative ABC transporter MDR1/ABCB1 and DNA topoisomerase IIa genes (Asakuno et al., 1994; Furukawa et al., 1998; Ohga et al., 1998) . YB-1 also selectively interacts with damaged DNA or RNA, and protects from cytotoxic effects following cellular exposure to cisplatin, mitomycin C, UV and oxygen radicals (Ohga et al., 1996; Ise et al., 1999) .
Royer and co-workers were the first to report that nuclear localization of YB-1 is associated with intrinsic MDR1 expression in human primary breast cancer (Bargou et al., 1997) . Immunostaining analysis of various human cancers also supported this result, and showed that nuclear expression of activated YB-1 was closely associated with the acquisition of P-glycoproteinmediated multidrug resistance (Kuwano et al., 2004) . YB-1 has also been shown to induce basal and 5-fluorouracil-induced expression of the major vault protein (MVP/LRP) gene, the promoter of which contains a Ybox (Stein et al., 2005) . In human malignancies, vault proteins are involved in acquiring drug resistance (Mossink et al., 2003) . Taken together, these findings suggest that nuclear localization of YB-1 might play a key role in the acquisition of global drug resistance through transcriptional activation of relevant genes and the repair of damaged DNA (Kuwano et al., 2004 ).
The nuclear localization of YB-1 is required for transcription and DNA repair in response to various environmental stimuli, such as adenovirus infection (Holm et al., 2002) , DNA-damaging agents, UV irradiation, hyperthermia (Stein et al., 2001) and serum stimulation (En-Nia et al., 2005) . However, as a nucleocytoplasmic shuttling protein, it is important to understand which signalling molecules are involved in the translocation of YB-1 into the nucleus. Koike et al. (1997) first reported the possible role of protein kinase C in YB-1 nuclear translocation in cancer cells exposed to UV irradiation, and highlighted the importance of the YB-1 C-terminal region in cytoplasmic retention. Other studies have suggested the involvement of additional molecules: thrombin-mediated YB-1 nuclear translocation was shown to be inhibited by protein tyrosine phosphatase inhibitor in endothelial cells (Stenina et al., 2000) , while Dooley et al. (2006) demonstrated the involvement of Jak1 in YB-1 nuclear translocation. Sutherland et al. (2005) recently reported that phosphorylation of YB-1 by Akt at serine 102 in the coldshock domain is required for YB-1 nuclear translocation in cancer cells. Another mechanism for nuclear translocation of YB-1 was shown to be promoted by various cytotoxic anticancer agents, which trigger the proteolytic cleavage by the 20S proteasome of the YB-1 C-terminal fragment containing the cytoplasmic retention signal (Sorokin et al., 2005) . In our present study, we have provided evidence that Akt activation is one of the mechanisms for nuclear translocalization of YB-1, and also that YB-1 regulates expression of various cell growth and malignant progression-related genes as well as global drug resistance-related genes including MDR1.
Results
Suppression of YB-1 leads to an enhancement of MDR-1 expression and decrease of CXCR-4 expression We previously reported that YB-1 was expressed in the nucleus in almost 30% of serous ovarian cancers, and that YB-1 nuclear-positive patients had a poor prognosis (Kamura et al., 1999) . As nuclear translocation of YB-1 is highly susceptible to environmental stimuli, we first examined whether the stress-inducing exogenous addition of serum could stimulate nuclear translocation of YB-1 in seven serum-deprived human ovarian cancer cell lines. Among the seven cell lines, nuclear YB-1 translocation was stimulated more than twofold in two: RMG-III and SKOV-3 ( Figure 1a ). In these two lines, serum incubation markedly enhanced Akt phosphorylation and increased translocation of YB-1 into the Although YB-1 is known to regulate the expression of several genes at the transcriptional level, the complete network of genes associated with YB-1 has not been elucidated. We therefore, explored the expression profile of YB-1 siRNA-treated SKOV-3 cells and mock-treated SKOV-3 cells using a high-density oligonucleotide microarray. We transfectd YB-1 siRNA into SKOV-3 cells at a concentration of 200 and 400 nM. Transfection of 200 nM YB-1 siRNA decreased expression of YB-1 mRNA by only 45%, whereas 400 nM YB-1 siRNA decreased by 70% (Figure 2 ). Of the 54 675 RNA transcripts and variants in the microarray, we identified 344 genes that were increased more than twofold and 534 genes that were decreased 0.5-fold or less in both 200 and 400 nM YB-1 siRNA-transfected cells (Supplementary Table S1 ). Upregulated genes were classified into 'cell cycle' (Po0.0001), 'cytoskeleton organization and biogenesis' (P ¼ 0.0003), 'cell growth and/or maintenance' (P ¼ 0.0005), and GO SLIMS Biological Process' (P ¼ 0.0013). Downregulated genes were classified into 'catalytic activity' (P ¼ 0.0007) and 'transferase' (P ¼ 0.0010). We selected 46 genes that we expected to be associated with drug resistance, cell growth, cancer malignant progression and cell signalling (Table 1) , and chose three of these for further study: MDR1, MVP/ LRP and chemokine (C-X-C motif) receptor 4 (CXCR4).
We used quantitative real-time PCR (QRT-PCR) to confirm whether expression of these three genes was modulated in YB-1 siRNA-transfected cells. Expression of CXCR4 decreased by 67%, whereas expression of MVP/LRP was unaffected by the siRNA (Figure 2 Pearson correlation and hierarchical cluster analysis of selected NCI-60 genes We next examined a database containing the expression profile of the National Cancer Institute (NCI)-60 panel from the Developmental Therapeutics Program (http:// www.dtp. nci.nih.gov/), shown as a log of mRNA expression level in the NCI screen. When the Pearson correlation coefficients were calculated, YB-1 was negatively correlated with MDR1 expression, positively correlated with CXCR4 expression and showed little correlation with MVP/LRP (Figure 3) . Moreover, the hierarchical dendrogram of gene expression revealed that YB-1 and CXCR4 belong to the same cluster, whereas MDR1 and MVP/LRP are clustered in a separate group (Figure 4) . Together, these NCI-60 panels suggest that cellular levels of YB-1 negatively modulate expression of MDR1 and positively regulate expression of CXCR4. In this cluster analysis, six ovarian cancer cell lines including SKOV-3 showed various correlation coefficiencies with YB-1 expression. Our oligonucleotide array analysis was performed only with SKOV-3, and correlation coefficiencies among ovarian cancer cell lines would depend upon which cell line was analysed.
Akt activity is prerequisite for nuclear translocation of YB-1and transcriptional regulation by YB-1 Phosphorylation of YB-1 by Akt is a necessary requirement for its translocation from the cytoplasm into the nucleus (Sutherland et al., 2005) . We therefore investigated the effect of two inhibitors of Akt activation (LY294002 and 1L-6-hydroxymethyl-chiro-inositol 2(R)-2-O-methyl-3-O-octadecylcarbonate) on serum-stimulated SKOV-3 cells. Both Akt inhibitors markedly blocked the nuclear accumulation of YB-1, whereas treatment with inhibitors of MEK (U0126), p38MAPK (SB203580) and JNK (SP600125) had no effect on nuclear translocation (Figure 5a ). In addition, phosphorylation of Akt was inhibited by LY294002 and octadecylcarbonate, but not by U0126, SB203580 and SP600125. Immunofluorescence analysis with a YB-1 antibody also demonstrated the predominant accumulation of YB-1 in the cytoplasm when treated with LY294002 and octadecylcarbonate (Figure 5b and c). As Akt inhibitors blocked the nuclear translocation of YB-1, we examined whether they could also affect expression of YB-1-regulated genes. CXCR4 expression was found to be downregulated in a dose-dependent manner following treatment with the Akt inhibitors when determined by QRT-PCR analysis (Figure 5d ). Treatment with Akt inhibitors upregulated the expression of MDR1, but not MVP/LRP.
SKOV-3 cells expressed high level of Akt1 protein, very low level of Akt2 protein, and no Akt3 protein when assayed by immunoblotting analysis (Figure 6a ). We introduced siRNA targeting Akt or ILK into SKOV-3 cells at a concentration of 100 and 10 nM, Figure 2 Effect of YB-1 knock down on expression of MDR1, MVP/LRP and CXCR4. SKOV-3 cells were treated with YB-1 siRNA for 48 h and then total RNA was prepared. QRT-PCR was performed for MDR1, MVP/LRP, CXCR4, YB-1 and housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The relative gene expression for each sample was determined using the formula 2 ðÀDCtÞ ¼ 2 ðCtðGAPDHÞÀCtðtargetÞÞ which reflected target gene expression normalized to GAPDH levels. Data were mean of three independent experiments; bars7s.d.
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Y Basaki et al respectively, and silencing effects of siRNA were analysed by immunoblotting ( Figure 6a ). In Akt siRNA almost completely silenced both Akt1 and Akt2, and siRNA for ILK, the upstream kinase for Akt, silenced ILK on protein level. Treatment with Akt siRNA and ILK siRNA resulted in a marked decrease in both pAkt expression and nuclear accumulation of YB-1 ( Figure 6a ). As both Akt and ILK siRNA blocked the nuclear translocation of YB-1, we examined their effects on expression of YB-1-regulated genes ( Figure 6b ).
Treatment with Akt and ILK siRNA downregulated the expression of CXCR4 gene, and upregulated the expression of MDR1 gene. By contrast there appeared no marked effect on the expression of MVP/LRP and YB-1 genes when treated with both siRNAs (Figure 6b ).
Effect of LY294002 treatment on Akt phosphorylation and YB-1 nuclear localization in SKOV-3 xenograft To further investigate the involvement of Akt in tumoural YB-1 nuclear localization, an in vivo xenograft High-density oligonucleotide array was performed on 400 nM YB-1 siRNA-treated SKOV-3 cells and mock-treated cells. siRNA duplexes were transfected using LipofectAMINE2000 with Opti-MEM mediums. At 48 h after siRNA transfection, total RNA was prepared, and subjected to double-stranded cDNA synthesis and in vitro transcription. The labeled cRNA was applied to the oligonucleotide microarray.
YB-1 as an Akt-regulated gene in ovarian cancer Y Basaki et al assay was performed. Administration of LY294002 (i.p.) to mice carrying SKOV-3 cell tumors inhibited the phosphorylation of Akt (Figure 7a and b) . Akt phosphorylation and YB-1 nuclear localization were also evaluated by immunohistochemical analysis. Tumors in the LY294002-treated group displayed a lower level of pAkt staining (3.370.5) than those in the control group, where the mean number of nuclear YB-1-positive cells was 24.773.4 (Figure 7c and d) . Taken together, these results suggest that nuclear localization of YB-1 in ovarian cancer cells is closely associated with Akt phosphorylation activity in vitro and in vivo.
Discussion
The nuclear localization of YB-1 is essential process for YB-1-driven transcription of various genes and DNA repair in cancer cells in response to various environmental stimuli. One should understand which signalling pathway specifically controls the translocation of YB-1 from cytoplasm into nucleus. Our previous study has demonstrated that PKC activates the nuclear localization of YB-1 in cancer cells treated with UV irradiation or cisplatin, and also that the C-terminal region of YB-1 was important for its cytoplasmic YB-1 as an Akt-regulated gene in ovarian cancer Y Basaki et al retention (Koike et al., 1997) . Sutherland et al. (2005) have presented more definitive mechanism at molecular basis that phosphorylation of serine 102 at cold-shock domain of YB-1 by Akt is essential for the nuclear YB-1 localization in breast cancer cells, and also that ILK phosphorylate its downstream Akt, resulting in activation of YB-1 and it nuclear localization. Consistent with this study, our present study also demonstrated that Akt as well as ILK played a critical role in the nuclear YB-1 localization and YB-1-driven-transcriptional control of various genes including CXCR4 and MDR1 in human ovarian cancer cells. In our present study, we examined whether expression of two multidrug resistance relevant genes, MVP/LRP and MDR1/ABCB1, was affected by knockdown of YB-1. Stein et al. (2005) have reported that the MVP/LRP gene is transcriptionally activated by YB-1 in response to cytotoxic anticancer agents including doxorubicin and 5-fluorouracil: MVP/LRP is an essential vault protein involving acquirement of multidrug resistance. However, in ovarian cancer cells, there was no causative association between the two genes when assayed by microarray and QRT-PCR. YB-1 might not regulate MVP/LRP expression in ovarian cancer cells used in our present study. In contrast, in human breast cancer cells, treatment with YB-1 siRNA markedly upregulated MVP/LRP expression (Shimoyama T, Nishio K, Basaki Y, Ono M and Kuwano M, unpublished data), suggesting that YB-1-induced regulation of MVP/LRP gene expression depends upon cancer cell types and/or types of stimuli. In contrast, knockdown or nuclear translocation inhibition of YB-1 upregulated expression of another drug resistance MDR1 gene in ovarian cancer cells. Various environmental stimuli often upregulated MDR1 gene in various human cancer cells through pleiotropic transcriptional regulations (Kuwano et al., 2004) . Our present study further presented a novel regulation of YB-1-induced negative control of MDR1 gene in ovarian cancer cells, and further study should be required to understand its underlying mechanism at molecular basis.
In our present study, we first observed that the knockdown of YB-1, ILK and Akt as well as an Akt inhibitor all downregulated expression of CXCR4 gene. Consistent with recent study by Sutherland et al. (2005) , ILK-Akt activation could be responsible for the nuclear localization of YB-1, resulting in enhanced expression of CXCR4 gene. The 2.6 Kb 5 0 -flanking region located upstream of the CXCR4 gene contains a TATA box and the transcription start site characteristic of a functional promoter (Caruz et al., 1998) and this region also contained putative consensus Y-box-binding site (inverted CCAAT box) form À685 to À681. However, it remains unknown whether ILK-Akt-induced activation of YB-1 is directly involved in the upregulation of CXCR4 gene.
CXCL12 (SDF-1a) is a specific ligand of CXCR4. CXCL12 induced a dose dependent proliferation of human ovarian cancer cells through its specific interaction with CXCR4 (Porcile et al., 2005) . This CXCR4 activation by CXCL12 further stimulated EGF receptor phosphorylation and its downstream kinases, ERK1/2, Akt and c-Src that might link several signallings of cell proliferation in ovarian cancer cells (Porcile et al., 2005) . On the other hand, VEGF, a potent angiogenic factor, induced upregulation of CXCR4 gene expression in vascular endothelial cells, and expression of both VEGF and CXCL12 was very high in ascites of patients with advanced ovarian cancers (Kryczek et al., 2005) . The cross-talk of CXCL12/CXCR4 with EGF/EGF receptor and/or VEGF/VEGF receptor might thus provide important signallings for both cell proliferation and angiogenesis in ovarian cancers.
CXCL12/CXCR4 pathway is also expected to be clinically involved in acquirement of malignant characteristics of human ovarian cancers. Of 14 chemokine receptors, only CXCR4 protein was found to be expressed in ovarian cancer cell lines and in ascites from patients with ovarian cancers (Scotton et al., 2001) . The CXCL12/CXCR4 pathway has been implicated in Figure 4 Hierarchical clustering of gene expression in NCI-60 screen. Hierarchical clustering can be used to group cell lines and genes in term of their patterns of gene expression. To obtain cluster trees for genes that showed distinct expression patterns across the 60 cell lines, we used the program 'Cluster' and 'Tree View' (http:// rana.lbl.gov/) with average linkage clustering and a correlation metric.
YB-1 as an Akt-regulated gene in ovarian cancer Y Basaki et al the development of tumor growth, angiogenesis and metastasis not only in ovarian cancer (Scotton et al., 2002) but also in other tumor types including breast cancer (Muller et al., 2001) , melanoma (Robledo et al., 2001; Murakami et al., 2002) and prostate cancer (Darash-Yahana et al., 2004) . Jiang et al. (2006) further demonstrated that CXCR4 expression could be an important prognostic marker for ovarian cancers: the rate of CXCR4 expression in refractory and recurrent group was significantly higher than that in nonrecurrent group. Our previous studies showed a significant association of nuclear localization of YB-1 with unfavorable prognosis of patients with ovarian cancers (Kamura et al., 1999; Huang et al., 2004) . Clinicopathological analysis whether nuclear expression of YB-1 can be associated with CXCR4 expression or CXCL12 (SDF-1a) in patients with ovarian cancers is now in progress.
Several studies have focused on the role of Akt/PI3K inhibitors as potential tumor suppressor agents. It has been reported that phosphorylation of Akt and mTOR, an Akt substrate, was frequently detected in ovarian cancer (Altomare et al., 2004) . In animal model of ovarian cancer, LY294002, a potent inhibitor of Akt activation, could inhibit cancer growth and ascites formation (Hu et al., 2000) . Our study also Figure 5 Akt activity is required for YB-1 nuclear accumulation and transcriptional regulation by YB-1. (a) The effect of kinase inhibitors on the nuclear accumulation of YB-1 in SKOV-3 cells. Inhibitors were added 3 h before serum stimulation and nuclear extracts were prepared 1 h after serum stimulation. Anti-YB-1 and anti-CREB immunoblots were performed with nuclear extracts, and anti-pAkt and anti-Akt immunoblots were performed on cytoplasmic extracts. CREB and Akt are shown as a loading control. (b) Immunofluorescent staining for YB-1. SKOV-3 cells were treated with LY294002 or octadecylcarbonate for 24 h and then stained with YB-1. Cells were fixed and permeabilized, incubated at 41C with the primary YB-1 antibody, then with the Alexa Flour 546-labelled secondary antibody. (c) Quantitative analysis of YB-1 nuclear localization in SKOV-3 cells as shown in Figure 2b . Data are mean of three independent experiments; bars 7s.d. (d) QRT-PCR for MDR1, MVP/LRP, CXCR4 and housekeeping gene GAPDH. The relative gene expression for each sample was determined using the formula 2 ðÀDCtÞ ¼ 2 ðCtðGAPDHÞÀCtðtargetÞÞ which reflected target gene expression normalized to GAPDH levels. Data were mean of three independent experiments; bars 7s.d.
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Y Basaki et al demonstrated that both Akt phosphorylation and YB-1 nuclear localization were blocked by administration of LY294002 in SKOV-3 xenograft model. Nuclear localization of YB-1 is induced through various pathways including Akt (see Introduction). The Akt-dependent pathway for YB-1 nuclear localization would provide further insight how Akt-targeting anticancer therapeutic strategy could be developed.
In conclusion, we have identified several genes that are regulated by YB-1 and/or its nuclear localization. Further immunohistochemical analysis should be required to elucidate the role of YB-1 in the expression of CXCR4 and other relevant genes that are associated with the clinicopathological characteristics in human ovarian cancers. Based on our present experimental results, we aim to present YB-1 and YB-1-dependent gene networks as molecular targets for the further development of novel anticancer therapeutic strategies.
Materials and methods
Cell culture and reagents OVCAR-3 and SKOV-3 were purchased from American Type Culture Collection (Manassas, VA, USA). RMG-I, RMG-II, RMG-III, RMBG and RTSG were kindly provided by Dr S Nozawa, Department of Obstetrics and Gynecology, Keio University. These cell lines were grown in DMEM supplemented with 10% fetal bovine serum (FBS) in an atmosphere of 5% CO 2 . LY294002 and U0126 were purchased from Sigma Chemical Co. (St Louis, MO, USA). 1L-6-hydroxymethyl-chiro-inositol 2(R)-2-O-methyl-3-O-octadecylcarbonate (Hu et al., 2000) , SB203580 (Cuenda et al., 1995) , and SP600125 (Bennett et al., 2001) were obtained from Calbiochem (San Diego, CA, USA). Anti-YB-1 was generated as described previously (Ohga et al., 1996) . Anti-CREB, anti-PKB/Akt, anti-phospho-PKB/Akt, anti-ILK, Akt siRNA and ILK siRNA were obtained from Cell Signaling Technology (Beverly, MA, USA).
Western blotting
Western blotting was performed as previously described (Kaneko et al., 2004) . Cells were lysed in buffer A (10 mM HEPES (pH7.9), 10 mM KCl, 10 mM EDTA, 1 mM DTT, 0.4% v/v IGEPAL, 1 mM Na 3 VO 4 , 1mM PMSF, and 10 mg/ml aprotinin and leupeptin) for 10 min on ice, and then centrifuged for 3 min at 15 000 r.p.m. The supernatant fractions (cytoplasmic soluble proteins) were collected. The nuclear pellet was then washed and then lysed in buffer C (20 mM HEPES (pH7.9), 200 mM NaCl, 1 mM EDTA, 5% v/v glycerol, 1 mM DTT, 1 mM Na 3 VO 4 , 1 mM PMSF and 10 mg/ml aprotinin and leupeptin). Lysates were incubated on ice for 2 h, and then centrifuged 15 000 r.p.m. for 5 min. The lysates were separated by sodium dodecyl sulfate-polyacryl amide gel electrophoresis (SDS-PAGE), and then were transferred to a nitrocellulose membrane. The membrane were incubated with the primary antibody and visualized with secondary antibody coupled to horseradish peroxidase (Cell Signaling Technology) (a) SKOV-3 cells were treated with Akt siRNA (100 nM), ILK siRNA (10 nM) or control siRNA (100 nM) for 48 h, and then cytoplasmic and nuclear extracts were prepared. Anti-Akt1, anti-Akt2, anti-Akt3, anti-ILK, anti-pAkt, and anti-YB-1 immunoblots were performed with cytoplasmic extracts, and anti-YB-1 and anti-CREB immunoblots were performed with nuclear extracts. (b) SKOV-3 cells were treated with Akt siRNA (100 nM) or ILK siRNA (10 nM) for 48 h and then total RNA was prepared. QRT-PCR was performed for MDR1, MVP/LRP, CXCR4, YB-1 and GAPDH housekeeping gene. The relative gene expression for each sample was determined using the formula 2 ðÀDCtÞ ¼ 2 ðCtðGAPDHÞÀCtðtargetÞÞ which reflected target genes normalized to GAPDH levels. Data were mean of three independent experiments; bars 7s.d.
YB-1 as an Akt-regulated gene in ovarian cancer Y Basaki et al and SuperSignal West Pico Chemiluminescent Substrate (Pierce, Rockford, IL, USA). Bands on Western blots were analysed densitometrically using Scion Image software (version 4.0.2; Scion Corp., Frederick, MD, USA).
Oligonucleotide microarray analysis
The siRNA corresponding to nucleotide sequences of the YB-1 (5 0 -GGU UCC CAC CUU ACU ACA U-3 0 ) was purchased from QIAGEN Inc. (Valencia, CA, USA). A negative control siRNA was obtained from Invitrogen (Carlsbad, CA, USA). siRNA duplexes were transfected using LipofectAMINE2000 and Opti-MEM medium (Invitrogen) according to the manufacturer's recommendations. Duplicate samples were prepared for microarray hybridization. At 48 h after siRNA transfection, total RNA was extracted from cell cultures using ISOGEN (Nippon Gene Co. Ltd., Tokyo, Japan). Total RNA (2 mg) was reverse-transcribed using GeneChip 3 0 -Amplification Reagents One-Cycle cDNA Synthesis Kit (Affymetrix Inc., Santa Clara, CA, USA) and then labeled with Cy5 or Cy3. The labeled cRNA was applied to the oligonucleotide microarray (Human Genome U133 Plus 2.0 Array, Affymetrix). The microarray was scanned on a GeneChip Scanner3000 and the image was analysed using a GeneChip Operating Software ver1.
Correlation analysis of gene expression, and clustering of cell lines and genes expression Gene expression data for the 60 human tumor cell lines were obtained from the Developmental Therapeutics Program (http://www.dtp. nci.nih.gov/), expressed as log of the mRNA levels in cell line/mRNA levels in reference pool in the NCI screen. Pearson correlation coefficients were calculated for each gene-gene pair. Hierarchical clustering can be used to group cell lines and genes in term of their patterns of gene expression. To obtain cluster trees for genes that showed distinct expression patterns across the 60 cell lines, we used the program 'Cluster' and 'Tree View' (http://rana.lbl.gov/) with average linkage clustering and a correlation metric (Eisen et al., 1998) .
Quantitative real-time polymerase chain reaction RNA was reverse transcribed from random hexamers using AMV reverse transcriptase (Promega, Madison, WI, USA). Real-time quantitative PCR was performed using the RealTime PCR system 7300 (Applied Biosystems, Foster City, CA, USA) as described previously (Maruyama et al., 2006) . In brief, the PCR amplification reaction mixtures (20 ml) contained cDNA, primer pairs, the dual-labeled fluorogenic probe, and TaqMan Universal PCR Master Mix (Applied Biosystems). The thermal cycle conditions included maintaining the reactions at 501C for 2 min and at 951C for 10 min, and then alternating for 40 cycles between 951C for 15 s and 601C for 1 min. The primer pairs and the probe were obtained from Applied Biosystems. The relative gene expression for each sample was determined using the formula 2 ðÀDCtÞ ¼ 2 ðCtðGAPDHÞÀCtðtargetÞÞ which reflected target gene expression normalized to GAPDH levels.
Immunofluorescence
Cells were plated on glass coverslips in six-well plates and allowed to attach overnight. Then, cells were rinsed with PBS and then fixed in 4% paraformaldehyde/PBS for 30 min. Cells were rinsed twice with PBS and then permeabilized with 0.5 ml of solution containing 5% BSA, 0.2% Triton X-100 in PBS for 90 min. After 1 h of blocking with 2% goat serum, the cells were incubated overnight with primary antibody at 41C in 1% BSA in PBS. Cells were then rinsed three times with PBS and incubated with 1 mg/ml of Alexa Flour 546-labeled secondary antibody (Molecular Probe, Eugene, OR, USA) in 1% BSA in PBS for 60 min. Coverslips were mounted on slide glasses using gel mount and viewed using an Olympus BX51 florescence microscope (Tokyo, Japan) and photographed with Olympus DP-70 digital camera.
Tumor xenograft study Male BALB/c nude mice were obtained from Kyudo Co., Ltd.
(Fukuoka, Japan). SKOV-3 cells were harvested and resuspended in PBS. The suspension was injected subcutaneously in the mice (5.0 Â 10 6 cells/0.1 ml/mouse). When tumors reached about 1000-2000 mm 3 , animals were randomly assigned to two groups of five mice each. The first group received i.p. injections of DMSO as control. The second group received i.p. injection of LY294002 at 50 mg/kg. At 1 h after LY294002 injection, mice were killed humanly (mice still anesthetized) by cervical dislocation and tumors were excised. For immunohistchemistry, one part of the tumor tissue was fixed in formalin and embed in paraffin.
